Tekla Capital Management’s PTC Therapeutics PTCT Stock Holding History

Tekla Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-120,827	Closed	-$6.13M	–	218
2020 Q2	$6.13M	Hold	120,827	–	–	0.23%	88
2020 Q1	$5.39M	Buy	120,827 +21,500	+22%	+$1.08M	0.24%	80
2019 Q4	$4.77M	Sell	99,327 -49,108	-33%	-$2.09M	0.18%	105
2019 Q3	$5.02M	Buy	148,435 +8,827	+6%	+$384K	0.22%	82
2019 Q2	$6.28M	Buy	139,608 +70,956	+103%	+$2.8M	0.26%	82
2019 Q1	$2.58M	Hold	68,652	–	–	0.1%	121
2018 Q4	$2.36M	Buy	68,652 +20,262	+42%	+$729K	0.1%	121
2018 Q3	$2.27M	Buy	+48,390	New	+$2M	0.08%	145
2018 Q2	–	Sell	-24,299	Closed	-$658K	–	187
2018 Q1	$658K	Buy	+24,299	New	+$616K	0.03%	164
2015 Q1	–	Sell	-119,150	Closed	-$6.17M	–	122
2014 Q4	$6.17M	Buy	119,150 +40,000	+51%	+$1.76M	0.29%	67
2014 Q3	$3.48M	Hold	79,150	–	–	0.16%	99
2014 Q2	$2.07M	Hold	79,150	–	–	0.19%	55
2014 Q1	$2.07M	Buy	+79,150	New	+$2.13M	0.21%	55

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Tekla Capital Management's PTCT Position: Q3 2020 in Review

Tekla Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2020, closing a stake of 120,827 shares — an estimated $6.13M sold.

Tekla Capital Management first reported a position in PTCT in Q1 2014 and held it in 13 quarters. The position peaked at $6.28M in Q2 2019. 196 funds tracked by Wall St. Rank hold PTCT as of Q3 2020.

Tekla Capital Management reported no remaining PTC Therapeutics position as of Q3 2020 after selling out during the quarter.
Tekla Capital Management sold 120,827 PTC Therapeutics shares in Q3 2020, an estimated $6.13M.
Tekla Capital Management first reported a position in PTC Therapeutics in Q1 2014 and held it in 13 quarters.
Tekla Capital Management's PTC Therapeutics position peaked at $6.28M in Q2 2019.
196 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2020.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.